Results from the heart preservation study presented on ISHLT
At ISHLT, the good results from the first six heart transplant patients from the study at Lund University Hospital were presented. The heart preservation technology used in the study is developed by Professor Stig Steen. Previous published preclinical experiments have demonstrated that the method has the potential to extend the time a heart can be preserved outside the body (Ex Vivo).
ISHLT (The International Society for Heart and Lung Transplantation) was held at the beginning of April, and at this conference, Professor Johan Nilsson presented the good results from the first six heart transplant patients from the ongoing study at Lund University Hospital. The results of the study indicate that the method is safe to use in humans. This means that larger randomized studies can be initiated with the heart preservation method. If the new method in larger studies demonstrates the same effect on humans as on animals, it will be possible to use significantly more donated hearts for transplantation. XVIVO Perfusion has through its cooperation agreement with Igelösa Life Science the commercial rights to Professor Stig Steen's research in heart transplantation.
Approximately 7,500 heart transplants are performed in the world each year and the limiting factor for more heart transplants are the lack of donated hearts and that the generally accepted maximum transport time today is about four hours. The new preservation method includes a machine that supplies the heart with important substances in an oxygenated solution (patent application submitted) before transplantation. In previous animal experiments using the new method, the preservation time for the donated heart has been significantly extended and that the donated heart´s function could be better preserved.
XVIVO Perfusion has further developed the machine, set up the production of the solution and submitted an application for approval to the Swedish Medical Products Agency to start a multicenter study with the new heart preservation technology. The company expects that the new multicenter study can begin as soon as the approval is in place.
April 23, 2019
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +46 735 192159, firstname.lastname@example.org
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com
Xvivo Perfusion AB (publ) submitted the following information through the agency of above contact person. The information was submitted for publication on April 23, 2019 at 5:00 p.m.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in Lund, Sweden and one office in Denver, the USA. The XVIVO share is listed on Nasdaq Stockholm and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com.
XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: email@example.com. Website: www.xvivoperfusion.com